Sign up to access all valuation multiples
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
1990
2.8K+
LTM Revenue $547M
LTM EBITDA $99.2M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Strides Pharma has a last 12-month revenue (LTM) of $547M and a last 12-month EBITDA of $99.2M.
In the most recent fiscal year, Strides Pharma achieved revenue of $503M and an EBITDA of $102M.
Strides Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Strides Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $547M | XXX | $503M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $259M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 51% | XXX | XXX | XXX |
| EBITDA | $99.2M | XXX | $102M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 20% | XXX | XXX | XXX |
| EBIT | n/a | XXX | $66.4M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $45.7M | XXX | $412M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 82% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $193M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Strides Pharma's stock price is INR 864 (or $10).
Strides Pharma has current market cap of INR 79.6B (or $912M), and EV of INR 96.4B (or $1.1B).
See Strides Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $912M | XXX | XXX | XXX | XXX | $0.50 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Strides Pharma has market cap of $912M and EV of $1.1B.
Strides Pharma's trades at 2.3x EV/Revenue multiple, and 12.7x EV/EBITDA.
Equity research analysts estimate Strides Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Strides Pharma has a P/E ratio of 20.0x.
See valuation multiples for Strides Pharma and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $912M | XXX | $912M | XXX | XXX | XXX |
| EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 11.1x | XXX | 12.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 17.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 20.0x | XXX | 3.0x | XXX | XXX | XXX |
| EV/FCF | 22.9x | XXX | 20.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialStrides Pharma's last 12 month revenue growth is 12%
Strides Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Strides Pharma's rule of 40 is 29% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Strides Pharma's rule of X is 47% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Strides Pharma and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 18% | XXX | XXX | XXX |
| Rule of 40 | 29% | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 47% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 38% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Strides Pharma acquired XXX companies to date.
Last acquisition by Strides Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Strides Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Strides Pharma founded? | Strides Pharma was founded in 1990. |
| Where is Strides Pharma headquartered? | Strides Pharma is headquartered in India. |
| How many employees does Strides Pharma have? | As of today, Strides Pharma has 2.8K+ employees. |
| Who is the CEO of Strides Pharma? | Strides Pharma's CEO is Mr. Badree Komandur. |
| Is Strides Pharma publicy listed? | Yes, Strides Pharma is a public company listed on NSE. |
| What is the stock symbol of Strides Pharma? | Strides Pharma trades under STAR ticker. |
| When did Strides Pharma go public? | Strides Pharma went public in 2000. |
| Who are competitors of Strides Pharma? | Similar companies to Strides Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Strides Pharma? | Strides Pharma's current market cap is $912M |
| What is the current revenue of Strides Pharma? | Strides Pharma's last 12 months revenue is $547M. |
| What is the current revenue growth of Strides Pharma? | Strides Pharma revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of Strides Pharma? | Current revenue multiple of Strides Pharma is 2.0x. |
| Is Strides Pharma profitable? | Yes, Strides Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Strides Pharma? | Strides Pharma's last 12 months EBITDA is $99.2M. |
| What is Strides Pharma's EBITDA margin? | Strides Pharma's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Strides Pharma? | Current EBITDA multiple of Strides Pharma is 11.1x. |
| What is the current FCF of Strides Pharma? | Strides Pharma's last 12 months FCF is $48.3M. |
| What is Strides Pharma's FCF margin? | Strides Pharma's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of Strides Pharma? | Current FCF multiple of Strides Pharma is 22.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
